SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference
January 13, 2025 06:30 ET
|
SpringWorks Therapeutics, Inc.
– Achieved $61.5 million and $172.0 million in preliminary fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively – – Ended 2024 with approximately $462...
SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 03, 2025 06:30 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., Jan. 03, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...
SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
November 26, 2024 07:00 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
November 12, 2024 09:25 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 12, 2024 06:30 ET
|
SpringWorks Therapeutics, Inc.
– Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors...
SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
November 11, 2024 07:00 ET
|
SpringWorks Therapeutics, Inc.
– Data from the pivotal Phase 2b ReNeu trial demonstrate that patients with NF1-PN achieved deep responses and improvements in health-related quality of life over the course of mirdametinib treatment...
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology
November 11, 2024 06:30 ET
|
SpringWorks Therapeutics, Inc.
– Mirdametinib treatment demonstrated significant confirmed objective response rates and a manageable safety profile in adults and children with NF1-PN – – Patients achieved deep and durable...
SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting
November 07, 2024 06:30 ET
|
SpringWorks Therapeutics, Inc.
– Long-term follow-up data highlight further reductions in tumor size, increase in ORR with additional CRs, sustained improvement in desmoid tumor symptoms, and consistent safety profile, now with a...
SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
November 05, 2024 07:00 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., Nov. 05, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...
SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
October 22, 2024 07:00 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...